ClinPharm Vault
Program and trial catalog
- Programs in current derived layer: 9
- CT.gov trials in current registry: 35
- Derived strategy view: Program strategy briefs
- Derived efficacy view: Cross-program efficacy summary
- Shared longitudinal comparison: Cross-program longitudinal UAS7 comparison
- Derived longitudinal view: Remibrutinib longitudinal UAS7
- Derived longitudinal view: Barzolvolimab longitudinal UAS7
- Derived longitudinal view: Rilzabrutinib longitudinal UAS7
| Program | Class | Trials | Primary pubs | Program page |
|---|---|---|---|---|
| Barzolvolimab | KIT | 8 | 3 | page |
| BLU-808 | KIT | 1 | 0 | page |
| Briquilimab | KIT | 3 | 0 | page |
| EP262 | MRGPRX2 | 2 | 0 | page |
| EVO756 | MRGPRX2 | 2 | 0 | page |
| Fenebrutinib | BTK | 2 | 1 | page |
| Remibrutinib | BTK | 16 | 4 | page |
| Rilzabrutinib | BTK | 1 | 1 | page |
| SEP-631 | MRGPRX2 | 0 | 0 | page |
Trial links
Barzolvolimab
- NCT04538794 - A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
- NCT04548869 - A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria
- NCT05368285 - A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
- NCT05405660 - A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
- NCT06445023 - A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- NCT06455202 - A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
- NCT07256392 - Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- NCT07266402 - A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
BLU-808
- NCT06931405 - Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
Briquilimab
- NCT06162728 - Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)
- NCT06353971 - A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines
- NCT06736262 - A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials
EP262
- NCT06050928 - Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria
- NCT06077773 - Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria
EVO756
- NCT06603220 - A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
- NCT06873516 - Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
Fenebrutinib
- NCT03137069 - A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).
- NCT03693625 - A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study
Remibrutinib
- NCT03926611 - Remibrutinib Phase 2b dose-finding CSU study (NCT03926611)
- NCT04109313 - Remibrutinib CSU phase 2 open-label extension (NCT04109313)
- NCT05030311 - REMIX-1 remibrutinib pivotal Phase 3 CSU study (NCT05030311)
- NCT05032157 - REMIX-2 remibrutinib pivotal Phase 3 CSU study (NCT05032157)
- NCT05048342 - Remibrutinib Japanese open-label Phase 3 CSU study (NCT05048342)
- NCT05170724 - Remibrutinib managed access program for CSU (NCT05170724)
- NCT05513001 - Remibrutinib long-term extension and randomized-withdrawal CSU study (NCT05513001)
- NCT05677451 - Remibrutinib adolescent Phase 3 CSU study (NCT05677451)
- NCT05795153 - Remibrutinib ambulatory blood pressure monitoring Phase 3 study (NCT05795153)
- NCT05976243 - Remibrutinib Phase 3 CIndU basket study (NCT05976243)
- NCT06042478 - Remibrutinib Phase 3b omalizumab-controlled CSU study (NCT06042478)
- NCT06865651 - Remibrutinib exploratory mixed chronic urticaria study (NCT06865651)
- NCT06868212 - Remibrutinib versus dupilumab Phase 3b CSU study (NCT06868212)
- NCT07358364 - Remibrutinib real-world multi-country effectiveness study (NCT07358364)
- NCT07358780 - Remibrutinib US real-world sub-study (NCT07358780)
- NCT07408219 - RELIEF remibrutinib early real-world effectiveness survey (NCT07408219)
Rilzabrutinib
- NCT05107115 - Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine
SEP-631
- No CT.gov-linked trials in current registry